M. G. Lebwohl, J. L. Sugarman, L. S. Gold, T. Lin, and G. Martin, “Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials”, J of Skin, vol. 3, p. S29, Nov. 2019.